NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 09 04:00PM ET
0.6600
Dollar change
+0.0547
Percentage change
9.04
%
Index- P/E- EPS (ttm)-0.21 Insider Own28.35% Shs Outstand37.74M Perf Week9.89%
Market Cap25.25M Forward P/E- EPS next Y-0.47 Insider Trans0.18% Shs Float27.42M Perf Month-30.96%
Enterprise Value23.70M PEG- EPS next Q-0.11 Inst Own16.80% Short Float4.91% Perf Quarter-24.13%
Income-7.67M P/S- EPS this Y-28.68% Inst Trans8.53% Short Ratio3.98 Perf Half Y-68.87%
Sales0.00M P/B10.60 EPS next Y-6.29% ROA-67.18% Short Interest1.35M Perf YTD-67.00%
Book/sh0.06 P/C2.91 EPS next 5Y-7.86% ROE-559.73% 52W High5.62 -88.26% Perf Year-86.61%
Cash/sh0.23 P/FCF- EPS past 3/5Y-91.03% - ROIC-238.48% 52W Low0.58 13.15% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.79% 9.19% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.14 Sales Y/Y TTM- Profit Margin- RSI (14)40.97 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.14 EPS Q/Q47.64% SMA20-7.59% Beta-0.82 Target Price10.75
Payout- Debt/Eq3.03 Sales Q/Q- SMA50-19.82% Rel Volume2.04 Prev Close0.61
Employees13 LT Debt/Eq0.37 EarningsMay 28 SMA200-61.33% Avg Volume338.53K Price0.66
IPOJan 31, 2024 Option/ShortNo / Yes EPS/Sales Surpr.0.00% - Trades Volume685,705 Change9.04%
Date Action Analyst Rating Change Price Target Change
Dec-12-24Initiated Rodman & Renshaw Buy $12
Oct-30-24Initiated H.C. Wainwright Buy $12
Sep-24-24Initiated Maxim Group Buy $12
Jul-09-25 08:30AM
Jul-07-25 04:35PM
Jun-16-25 04:35PM
09:50AM
Jun-09-25 08:30AM
08:30AM Loading…
May-16-25 08:30AM
May-14-25 04:30PM
Apr-29-25 09:15AM
09:15AM
Apr-11-25 08:30AM
Apr-08-25 08:30AM
Apr-02-25 08:30AM
Mar-31-25 04:25PM
Mar-27-25 08:30AM
Mar-21-25 08:30AM
08:35AM Loading…
Mar-14-25 08:35AM
Mar-12-25 01:12PM
Mar-04-25 08:30AM
Feb-27-25 08:30AM
Feb-05-25 09:15AM
Dec-30-24 04:30PM
02:12PM
Dec-23-24 07:55AM
Nov-19-24 09:15AM
Nov-14-24 09:15AM
Nov-12-24 04:20PM
Oct-29-24 09:15AM
Oct-28-24 09:31AM
Oct-21-24 07:45AM
Oct-18-24 08:30AM
09:15AM Loading…
Oct-16-24 09:15AM
Oct-11-24 09:31AM
Sep-30-24 09:31AM
Sep-19-24 09:31AM
Sep-12-24 09:31AM
Sep-06-24 09:31AM
Aug-20-24 09:31AM
Aug-07-24 06:52PM
Jul-15-24 09:31AM
Jun-25-24 09:31AM
Jun-13-24 09:31AM
Jun-06-24 09:31AM
May-15-24 04:30PM
09:54AM
May-14-24 05:24PM
May-07-24 09:31AM
Apr-25-24 08:00AM
Apr-11-24 09:31AM
Apr-04-24 09:31AM
Mar-28-24 09:31AM
Mar-19-24 09:31AM
Mar-13-24 09:31AM
Mar-06-24 09:31AM
Feb-29-24 05:44PM
Feb-20-24 09:31AM
Feb-13-24 09:31AM
Feb-08-24 09:31AM
Feb-06-24 09:31AM
Jan-31-24 10:00AM
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khoja HamidChief Scientific OfficerMay 27 '25Buy0.8420,00016,80031,250May 27 05:56 PM
O'HEERON PETEChief Executive OfficerAug 12 '24Buy1.918,50016,2696,056,647Aug 12 09:58 PM
Khoja HamidChief Scientific OfficerAug 12 '24Buy1.9010,00019,00011,250Aug 12 09:58 PM